ARS Pharmaceuticals (NASDAQ:SPRY) Sees Large Volume Increase

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Rating) saw an uptick in trading volume on Monday . 1,088,338 shares traded hands during mid-day trading, an increase of 17% from the previous session’s volume of 928,725 shares.The stock last traded at $7.83 and had previously closed at $8.04.

Wall Street Analyst Weigh In

Separately, Wedbush began coverage on shares of ARS Pharmaceuticals in a research note on Tuesday, January 31st. They issued an “outperform” rating and a $10.00 target price for the company.

ARS Pharmaceuticals Stock Performance

The firm has a 50 day moving average price of $6.84.

Insider Transactions at ARS Pharmaceuticals

In related news, Director Laura Shawver sold 42,900 shares of the business’s stock in a transaction that occurred on Tuesday, May 9th. The shares were sold at an average price of $5.31, for a total transaction of $227,799.00. Following the completion of the transaction, the director now owns 210,346 shares of the company’s stock, valued at $1,116,937.26. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 34.40% of the company’s stock.

Hedge Funds Weigh In On ARS Pharmaceuticals

Several hedge funds have recently bought and sold shares of SPRY. Baker BROS. Advisors LP purchased a new position in ARS Pharmaceuticals during the first quarter valued at approximately $13,062,000. Geode Capital Management LLC purchased a new position in ARS Pharmaceuticals during the first quarter valued at approximately $2,627,000. Jane Street Group LLC purchased a new position in ARS Pharmaceuticals during the first quarter valued at approximately $895,000. State Street Corp grew its stake in ARS Pharmaceuticals by 50.4% during the first quarter. State Street Corp now owns 129,191 shares of the company’s stock valued at $841,000 after acquiring an additional 43,300 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in ARS Pharmaceuticals during the first quarter valued at approximately $84,000.

ARS Pharmaceuticals Company Profile

(Get Rating)

ARS Pharmaceuticals, Inc develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.